Multifocal ERG and Microperimetry Changes in Response to Ranibizumab Treatment of Neovascular AMD: Randomized Phase 2 Open-Label Study

References

• Pennington KL, DeAngelis MM. Epidemiology of age-related macular degeneration (AMD): associations with cardiovascular disease phenotypes and lipid factors. Eye Vis (Lond). 2016;3(34):1–20.
   Google Scholar
• Congdon N, O’Colmain B, Klaver CC, et al. Causes and prevalence of visual impairment among adults in the United States. Arch Ophthalmol. 2004;122(4):477–485.
   PubMed Web of Science ®Google Scholar
• Ferrara N, Damico L, Shams N, et al. Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration. Retina. 2006;26(8):859–870. doi:10.1097/01.iae.0000242842.14624.e7
   PubMed Web of Science ®Google Scholar
• Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;355(14):1419–1431. doi:10.1056/NEJMoa054481
   PubMed Web of Science ®Google Scholar
• Brown DM, Kaiser PK, Michels M, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med. 2006;355(14):1432–1444. doi:10.1056/NEJMoa062655
   PubMed Web of Science ®Google Scholar
• Martin DF, Maguire MG, Fine SL, et al. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology. 2012;119(7):1388–1398. doi:10.1016/j.ophtha.2012.03.053
   PubMed Web of Science ®Google Scholar
• Busbee BG, Ho AC, Brown DM, et al. Twelve-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration. Ophthalmology. 2013;120(5):1046–1056. doi:10.1016/j.ophtha.2012.10.014
   PubMed Web of Science ®Google Scholar
• Chakravarthy U, Harding SP, Rogers CA, et al. Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial. Ophthalmology. 2012;119(7):1399–1411. doi:10.1016/j.ophtha.2012.04.015
   PubMed Web of Science ®Google Scholar
• Krebs I, Schmetterer L, Boltz A, et al. A randomised double-masked trial comparing the visual outcome after treatment with ranibizumab or bevacizumab in patients with neovascular age-related macular degeneration. Br J Ophthalmol. 2013;97(3):266–271. doi:10.1136/bjophthalmol-2012-302391
   PubMed Web of Science ®Google Scholar
• Gupta OP, Shienbaum G, Patel AH, et al. A treat and extend regimen using ranibizumab for neovascular age-related macular degeneration clinical and economic impact. Ophthalmology. 2010;117(11):2134–2140.
   PubMed Web of Science ®Google Scholar
• Danyliv A, Glanville J, McCool R, et al. The clinical effectiveness of ranibizumab treat and extend regimen in nAMD: systematic review and network meta-analysis. Adv Ther. 2017;34(3):611–619. doi:10.1007/s12325-017-0484-0
   Web of Science ®Google Scholar
• Thavikulwat AT, Jacobs-El N, Kim JS, et al. Evolution of geographic atrophy in participants treated with ranibizumab for neovascular age-related macular degeneration. Ophthalmol Retina. 2017;1(1):34‐41. doi:10.1016/j.oret.2016.09.005
   Google Scholar
• Ferris FL 3rd, Kassoff A, Bresnick GH, Bailey I. New visual acuity charts for clinical research. Am J Ophthalmol. 1982;94(1):91–96. doi:10.1016/0002-9394(82)90197-0
   PubMed Web of Science ®Google Scholar
• Alexander P, Mushtaq F, Osmond C, Amoaku W. Microperimetric changes in neovascular age-related macular degeneration treated with ranibizumab. Eye (Lond). 2012;26(5):678–683. doi:10.1038/eye.2012.7
   Web of Science ®Google Scholar
• Gerth C. The role of the ERG in the diagnosis and treatment of age-related macular degeneration. Doc Ophthalmol. 2009;118(1):63–68. doi:10.1007/s10633-008-9133-x
   PubMed Web of Science ®Google Scholar
• Ho AC, Busbee BG, Regillo CD, et al. Twenty-four-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration. Ophthalmology. 2014;121(11):2181–2192. doi:10.1016/j.ophtha.2014.05.009
   PubMed Web of Science ®Google Scholar
• Dirani A, Mantel I. Ranibizumab treatment history as predictor of the switch-response to aflibercept: evidence for drug tolerance. Clin Ophthalmo. 2018;12:593–600. doi:10.2147/OPTH.S160367
   Web of Science ®Google Scholar
• Eghoj MS, Sorensen TL. Tachyphylaxis during treatment of exudative age-related macular degeneration with ranibizumab. Br J Ophthalmol. 2011;96(1):21–23. doi:10.1136/bjo.2011.203893
   Web of Science ®Google Scholar
• Gasperini JL, Fawzi AA, Khondkaryan A, et al. Bevacizumab and ranibizumab tachyphylaxis in the treatment of choroidal neovascularisation. Br J Ophthalmol. 2012;96(1):14‐20. doi:10.1136/bjo.2011.204685
   Web of Science ®Google Scholar
• Holz FG, Figueroa MS, Bandello F, et al. Ranibizumab treatment in treatment-naive neovascular age-related macular degeneration: results from luminous, a global real-world study. Retina. 2019:10.1097/IAE.0000000000002670. doi:10.1097/IAE.0000000000002670.
   Web of Science ®Google Scholar
• Chakravarthy U, Harding SP, Rogers CA, et al. Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial. Lancet. 2013;382(9900):1258–1267. doi:10.1016/S0140-6736(13)61501-9
   PubMed Web of Science ®Google Scholar
• The CATT Research Group. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med. 2011;364(20):1897–1908. doi:10.1056/NEJMoa1102673
   PubMed Web of Science ®Google Scholar
• Young B, Eggenberger E, Kaufman D. Current electrophysiology in ophthalmology: a review. Curr Opin Ophthalmol. 2012;23(6):497–505. doi:10.1097/ICU.0b013e328359045e
   Web of Science ®Google Scholar
• Vincent A, Robson AG, Holder GE. Pathognomonic (diagnostic) ERGs. A review and update. Retina. 2013;33(1):5–12. doi:10.1097/IAE.0b013e31827e2306
   PubMed Web of Science ®Google Scholar
• Hood DC, Frishman LJ, Saszik S, Viswanathan S. Retinal origins of the primate multifocal ERG: implications for the human response. Invest Ophthalmol Vis Sci. 2002;43(5):1673–1685.
   PubMed Web of Science ®Google Scholar
• Gerth C, Garcia SM, Ma L, Keltner JL, Werner JS. Multifocal electroretinogram: age-related changes for different luminance levels. Graefes Arch Clin Exp Ophthalmol. 2002;240(3):202–208. doi:10.1007/s00417-002-0442-6
   Web of Science ®Google Scholar
• Gerth C, Delahunt PB, Alam S, Morse LS, Werner JS. Cone-mediated multifocal electroretinogram in age-related macular degeneration: progression over a long-term follow-up. Arch Ophthalmol. 2006;124(3):345–352. doi:10.1001/archopht.124.3.345
   PubMedGoogle Scholar
• Reinsberg M, Hilgers R, Ludeke I, et al. Testing the clinical value of multifocal electroretinography and microperimetry and the effects of intravitreal therapy with ranibizumab on macular function in the course of wet age-related macular degeneration: a 1-year prospective study. Clin Ophthalmol. 2017;11:621–629. doi:10.2147/OPTH.S123513
   Web of Science ®Google Scholar
• Gemenetzi M, Lotery AJ, Patel PJ. Risk of geographic atrophy in age-related macular degeneration patients treated with intravitreal anti-VEGF agents. Eye (Lond). 2017;31(1):1–9. doi:10.1038/eye.2016.208
   PubMed Web of Science ®Google Scholar
• Grunwald JE, Daniel E, Huang J, et al. The CATT research group risk factors for the development of GA in CATT. Ophthalmology. 2014;121(1):150–161. doi:10.1016/j.ophtha.2013.08.015
   PubMed Web of Science ®Google Scholar
• Cohen SY, Oubraham H, Uzzan J, et al. Causes of unsuccessful ranibizumab treatment in exudative age-related macular degeneration in clinical settings. Retina. 2012;32(8):1480–1485.
   Web of Science ®Google Scholar
• Campa C, Hagan R, Sahni JN, et al. Early multifocal electroretinogram findings during intravitreal ranibizumab treatment for neovascular age-related macular degeneration. Invest Ophthalmol Vis Sci. 2011;52:3446–3451.
   PubMed Web of Science ®Google Scholar
• Dinc UA, Yeneral M, Gorgun E, Oncel M. Assessment of macular function by microperimetry in intermediate age-related macular degeneration. Eur J Ophthalmol. 2008;18(4):595–600.
   Web of Science ®Google Scholar
• Parravano M, Oddone F, Tedeschi M, et al. Retinal functional changes measured by microperimetry in neovascular age-related macular degeneration treated with ranibizumab: 24-month results. Retina. 2010;30(7):1017‐1024. doi:10.1097/IAE.0b013e3181cfd3c6
   Web of Science ®Google Scholar
• Wu Z, Ayton LN, Guymer RH, Luu CD. Intrasession test-retest variability of microperimetry in age-related macular degeneration. Invest Ophthalmol Vis Sci. 2013;54(12):7378–7385. doi:10.1167/iovs.13-12617
   Web of Science ®Google Scholar
• Chen FK, Patel PJ, Xing W, et al. Test–retest variability of microperimetry using the nidek MP1 in patients with macular disease. Invest Ophthalmol Vis Sci. 2009;50(7):3464–3472. doi:10.1167/iovs.08-2926
   Web of Science ®Google Scholar
• Vujosevic S, Pucci P, Casciano M, et al. Long-term longitudinal modifications in mesopic microperimetry in early and intermediate age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol. 2017;255(2):301–309. doi:10.1007/s00417-016-3466-z
   Web of Science ®Google Scholar